New York-based Kallyope and Danish company Novo Nordisk signed a research collaboration and option deal to discover novel therapeutics to treat obesity and diabetes.
The names of the tools may be changing, but the goal for brand managers remains the same in 2018: getting as close as possible to real patients and their needs.
Executives from 2017 Manny Award winners/finalists and other healthcare communications agencies participated in this Q&A forum of industry topics.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
Two have been around in the pharmaceutical industry for a long time, and one is a relative newcomer. In considering this year’s pharma innovators to profile, the results of their accomplishments, not how long they have been around, steered the direction of this feature. Donna Murphy, global CEO of the recently formed agency network Havas Health & You; Abraham Gutman, president and CEO of AG Mednet; and C. David Nicholson, executive VP and chief R&D officer of Allergan, are being saluted for bringing new innovations to the fields of pharmaceutical advertising, clinical trial imaging and R&D, and their accomplishments are expected to echo into the future.
The Trump administration issued a finalized rule that will enable millions of Americans to buy skimpy health insurance plans that do not comply with key Obamacare coverage requirements.
Roche is paying $2.4 billion to buy the rest of Foundation Medicine, raising the Swiss drugmaker’s bet on the U.S. genomic profiling group’s ability to personalize cancer care.
Kentucky’s attorney general sued Walgreens Boots Alliance Inc., accusing the company of playing a role in propagating an opioid epidemic in the state.
Johnson & Johnson has accepted private equity firm Platinum Equity’s $2.1 billion buyout offer for the company’s LifeScan unit.
Rockville, Md.-based REGENXBIO snagged $100 million from Novartis under its license agreement with gene-therapy company AveXis, which the Swiss company acquired for $8.7 billion earlier in 2018.
New Haven, Conn.-based Melinta Therapeutics snagged $123 million in a public offering of 22,000,000 shares of its common stock.
Translate Bio, headquartered in Lexington, Massachusetts, and Paris-based Sanofi are teaming up to develop five vaccines.
Billionaire Patrick Soon-Shiong plans to take an experimental cancer treatment company public during 2018 and has begun hiring bankers, the biotechnology entrepreneur told Reuters.
Ipsen plans to relocate the French company’s U.S. operations from New Jersey to Kendall Square in Cambridge, Mass.
The Bill & Melinda Gates Foundation spun off a biotech company called The Bill & Melinda Gates Medical Research Institute (MRI) located in Boston.
Biogen, headquartered in Cambridge, Massachusetts, signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.
Johnson & Johnson received a binding offer to sell its Advanced Sterilization Products (ASP) business to Fortive Corporation. The deal is valued at $2.8 billion.
Alkermes, headquartered in Dublin, Ireland, received a $50 million milestone payment from Cambridge, Massachusetts-based Biogen.
Axovant Sciences announced that the biotech start-up licensed exclusive worldwide rights to OXB-102, now dubbed AXO-Lenti-PD, from Oxford BioMedica.
Pfizer Inc. announced plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle.
The tenth annual Dealmakers’ Intentions Study from Syneos Health Consulting, an industry-leading consulting firm specializing in the biopharmaceutical industry, concludes that the dealmaking environment will continue to accelerate with buyers becoming more selective in ensuring they have the most appropriate assets and corresponding deals in place.
Nimbus Therapeutics, headquartered in Cambridge, Massachusetts, raised an additional $65 million in financing. Early investors participated, including Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures and Schrodinger.
Here is a look at some notable programs that have been shuttered by biopharmaceutical companies during 2018.
Allergan plans to sell off both businesses as the company’s CEO works to end a steep slide in the drugmaker’s share price.